Medical Oncology Unit, La Maddalena Clinic for Cancer , Palermo, Italy.
Department of Internal Medicine "Promise", University of Palermo , Palermo, Italy.
Expert Opin Drug Saf. 2020 Aug;19(8):945-954. doi: 10.1080/14740338.2020.1781814. Epub 2020 Jun 22.
The discovery and the clinical availability of novel cyclin-dependent kinases 4 and 6 inhibitors have profoundly changed the therapeutic scenario of metastatic hormone receptor-positive breast carcinoma. Among these inhibitors, abemaciclib can induce potent and sustained cell cycle arrest and immune system stimulation.
This review summarizes the safety profile and clinical efficacy data on abemaciclib alone or in combination with aromatase inhibitors or fulvestrant in metastatic hormone receptor-positive breast carcinoma. The management of patients treated with abemaciclib is the object of this paper.
As shown in phase 2 and 3 clinical trials on efficacy and tolerability, abemaciclib is a potentially convenient, safe, and effective agent for the treatment of patients with advanced hormone receptor-positive patients. Orally administered abemaciclib in combination with aromatase inhibitors or fulvestrant has the potential to allow significant improvement in survival outcomes, quality of life, response rate, and duration of response even in poor prognosis subgroups. Adequate patients' information, clinical selection, and prompt, proactive management of side effects are mandatory.
新型细胞周期蛋白依赖性激酶 4 和 6 抑制剂的发现和临床应用，极大地改变了转移性激素受体阳性乳腺癌的治疗格局。在这些抑制剂中，阿贝西利可诱导强效和持续的细胞周期停滞，并刺激免疫系统。
本文总结了阿贝西利单药或联合芳香化酶抑制剂或氟维司群治疗转移性激素受体阳性乳腺癌的安全性特征和临床疗效数据。本文的重点是阿贝西利治疗患者的管理。
在疗效和耐受性的 2 期和 3 期临床试验中显示，阿贝西利是一种具有潜在优势的方便、安全、有效的治疗晚期激素受体阳性患者的药物。阿贝西利联合芳香化酶抑制剂或氟维司群口服给药，有可能使生存结局、生活质量、缓解率和缓解持续时间得到显著改善，即使在预后较差的亚组中也是如此。必须充分告知患者信息、进行临床选择，并及时、积极地处理不良反应。
